NDAORALTABLET, EXTENDED RELEASE3 Generics Approved
Approved
Feb 2003
Lifecycle
LOE Approaching
Competitive Pressure
60/100
Data completeness
3/8 — Basic
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CARDIZEM LA is an extended-release oral tablet formulation of diltiazem hydrochloride, a non-dihydropyridine calcium channel blocker. It is indicated for hypertension and angina pectoris, working by inhibiting calcium influx into vascular smooth muscle and cardiac cells to reduce blood pressure and myocardial oxygen demand. The mechanism provides cardioprotective effects through AV nodal conduction delay and heart rate reduction.
$2.0MPart D
LOE ApproachingDeclining
Product is in late-stage lifecycle with modest Part D utilization; commercial teams are likely in maintenance mode preparing for generic transition and focus on volume retention.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on CARDIZEM LA offers experience in mature product management, managed care negotiation, and generic transition strategy—valuable skills in a competitive pharma market. Roles are focused on defending market share against generics and optimizing profitability rather than driving growth, limiting visibility for advancement to higher-profile launches.
Brand Manager
Worked on CARDIZEM LA at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.